Anavex Life Sciences (AVXL)
(Delayed Data from NSDQ)
$3.87 USD
-0.16 (-3.97%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $3.88 +0.01 (0.26%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Anavex Life Sciences Corp. [AVXL]
Reports for Purchase
Showing records 1 - 20 ( 155 total )
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Pipeline Progress; Fiscal 1Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Reports the Quarter: $143M in Cash
Provider: Dawson James Securities, Inc.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Anavex Life Sciences announces publication of findings from first-in-human study of ANAVEX3-71
Provider: Dawson James Securities, Inc.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
ANAVEX3-71 Phase 2 Schizophrenia Trial Cleared by FDA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Phase 2 Trial of ANAVEX3-71 for the Treatment of Schizophrenia ? This is Something New!
Provider: Dawson James Securities, Inc.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Blarcamesine Disappoints in Rett Syndrome Trial; Lowering PT to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Rett Syndrome Top Line Results - A Split Decision but Look Deeper and You?ll See There Is Hope
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Blarcamesine Slated For Regulatory Submission in Alzheimer''s; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Rett Syndrome - It''s in the Genes
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Anavex Received Agreement from the Committee for Medicinal Products for Human Use
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: How Much is an Approval in Alzheimer''s Worth?
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Fiscal 2023 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for AVXL 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Blarcamesine Regulatory Process Initiated in Europe; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: How Much is an Approval in Alzheimer''s Worth?
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Preclinical Data Suggest ANAVEX3-71 Anti-Alzheimer''s Impact; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: ANAVEX 3-71 for Prevention in Alzheimer''s Disease
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Anavex?s P2b/3 Trial of ANAVEX2-73 in Alzheimer?s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
F3Q23 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R